Catalent Inc (NYSE:CTLT) Director John J. Greisch purchased 13,000 shares of the business’s stock in a transaction on Thursday, November 8th. The shares were acquired at an average cost of $37.61 per share, with a total value of $488,930.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Catalent stock opened at $38.22 on Wednesday. Catalent Inc has a 1 year low of $34.24 and a 1 year high of $47.87. The firm has a market cap of $5.52 billion, a price-to-earnings ratio of 23.13, a price-to-earnings-growth ratio of 2.37 and a beta of 1.45. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.61.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.04. The firm had revenue of $551.80 million for the quarter, compared to analysts’ expectations of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.21 EPS. On average, sell-side analysts forecast that Catalent Inc will post 1.64 EPS for the current fiscal year.

Several brokerages have issued reports on CTLT. UBS Group began coverage on Catalent in a report on Tuesday, October 9th. They set a “neutral” rating and a $48.00 price target for the company. JPMorgan Chase & Co. raised their price target on Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Wednesday, August 29th. Zacks Investment Research raised Catalent from a “sell” rating to a “hold” rating in a report on Tuesday, October 30th. First Analysis raised Catalent from a “neutral” rating to an “outperform” rating and cut their price target for the company from $47.00 to $43.00 in a report on Wednesday, November 7th. Finally, ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. Catalent currently has a consensus rating of “Buy” and a consensus price target of $48.11.

A number of hedge funds have recently bought and sold shares of the business. Utah Retirement Systems increased its position in Catalent by 9.4% during the 3rd quarter. Utah Retirement Systems now owns 26,800 shares of the company’s stock worth $1,220,000 after buying an additional 2,300 shares during the period. Riverhead Capital Management LLC increased its position in Catalent by 19.7% during the 3rd quarter. Riverhead Capital Management LLC now owns 13,987 shares of the company’s stock worth $637,000 after buying an additional 2,300 shares during the period. Mutual of America Capital Management LLC increased its position in Catalent by 7.2% during the 3rd quarter. Mutual of America Capital Management LLC now owns 122,855 shares of the company’s stock worth $5,596,000 after buying an additional 8,266 shares during the period. Tower Research Capital LLC TRC increased its position in Catalent by 763.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 14,573 shares of the company’s stock worth $664,000 after buying an additional 12,885 shares during the period. Finally, William Blair Investment Management LLC increased its position in Catalent by 26.7% during the 3rd quarter. William Blair Investment Management LLC now owns 4,364,177 shares of the company’s stock worth $198,788,000 after buying an additional 920,869 shares during the period. Hedge funds and other institutional investors own 90.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/11/14/john-j-greisch-purchases-13000-shares-of-catalent-inc-ctlt-stock.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Recommended Story: Index Funds

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.